Clinical pharmacokinetics of metformin

Clinical Pharmacokinetics

Volumn 30, Issue 5, 1996, Pages 359-371

  Scheen, André J ^a,b  

^a CHU SART TILMAN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; CIMETIDINE; GUAR GUM; METFORMIN;

AGED; AREA UNDER THE CURVE; CLINICAL TRIAL; CREATININE CLEARANCE; DIURESIS; DRUG DOSE; DRUG HALF LIFE; DRUG OVERDOSE; DRUG STRUCTURE; GASTROINTESTINAL ABSORPTION; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

EID: 0029933886     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630050-00003     Document Type: Review

References (74)

1. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72
2. Hermann LS, Melander A. Biguanides: basic aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, et al., editors. International textbook of diabetes mellitus. Chichester: Wiley, 1992: 773-95
3. Lefèbvre PJ, Scheen AJ. Management of non-insulin-dependent diabetes mellitus. Drugs 1992; 44 Suppl. 3: 29-38
4. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-49
5. Scheen AJ, Lefèbvre PJ. Pathophysiology of type 2 diabetes. In: Kuhlmann J, Puls W, editors. Handbook of experimental pharmacology, oral antidiabetics. Berlin: Springer Verlag, 1996: 7-42
6. Cohen RD, Woods HF. Lactic acidosis revisited. Diabetes 1983; 32: 181-91
7. Schäfer G. Biguanides: a review of history, pharmacodynamics and therapy. Diabete Metab 1983; 9: 148-63
8. Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res 1994; 30: 187-228
9. Andreani D, Lefèbvre P, editors. Metformin: mechanisms of action and clinical use. Diabetes Metab Rev 1995; 11 Suppl. 1: S1-S108
10. DeFronzo RA, Goodman AN, Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541-9
11. Pignard P. Dosage spectrophotométrique du N-N-diméthyl biguanide dans le sang et l'urine. Ann Biol Clin 1962; 20: 325-33
12. Garrett ER, Tsau J, Hinderling PH. Application of ion-pair methods to drug extraction from biological fluids: II. Quantitative determination of biguanides in biological fluids and comparison of protein binding estimates. J Pharm Sci 1972; 61: 1411-8
13. Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978; 24: 683-93
14. Lennard MS, Casey C, Tucker GT, et al. Determination of metformin in biological samples. Br J Clin Pharmacol 1978; 6: 183-5
15. Brohon J, Noel M. Determination of metformin in plasma at therapeutic levels by gas-liquid chromatography using nitrogen detector. J Chromatogr 1978; 146: 148-51
16. Charles BG, Jacobsen NW, Ravenscroft PJ. Rapid liquid-chromatographic determination of metformin in plasma and urine. Clin Chem 1981; 27: 434-6
17. Benzi L, Marchetti P, Cecchetti P, et al. Determination of metformin and phenformin in human plasma and urine by reverse-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl 1986; 375: 184-9
18. Lacroix C, Danger P, Wojciechowski F. Microdosage de la metformine plasmatique et intra-érythrocytaire par chromatographie en phase liquide. Ann Biol Clin 1991; 49: 98-101
19. Huupponen R, Ojala Karlsson P, Rouru J, et al. Determination of metformin in plasma by high-performance liquid chromatography. J Chromatogr Biomed Appl 1992; 583: 270-3
20. Ohta M, Iwasaki M, Kai M, et al. Determination of a biguanide, metformin, by high-performance liquid chromatography with precolumn fluorescence derivatization. Anal Sci 1993; 9: 217-20
21. Rizk MS, Abdel Fattah HM, Issa YM, et al. A new metformin selective plastic membrane electrode based on metformin tetraphenylborate. Anal Lett 1993; 26: 415-28
22. Caille G, Lacasse Y, Raymond M, et al. Bioavailability of metformin in tablet form using a new high pressure liquid chromatography assay method. Biopharm Drug Dispos 1993; 14: 257-63
23. Pentikäinen PJ, Neuvonen PJ, Penttilä A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979; 16: 195-202
24. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981; 12: 235-46
25. Sambol NC, O'Connor MD, Lin ET, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of metformin HCl (Met) in healthy (H) individuals and individuals with noninsulin-dependent diabetes mellitus (NIDDM) [abstract]. Clin Pharmacol Ther 1993; 53: 211
26. Noel M. Kinetic study of normal and sustained release dosage forms of metformin in normal subjects. Res Clin For 1979; 1: 35-45
27. Isnard F, Lavieuville M, Gut M. Pharmacocinétique de la metformine. In: Journées de Diabétologie de l'Hôtel-Dieu. Paris: Flammarion, Médecine-Sciences, 1980: 305-12
28. Karttunen P, Uusitupa M, Lamminsivu U. The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation. Int J Clin Pharmacol Ther Toxicol 1983; 21: 31-6
29. Arafat T, Kaddoumi A, Shami M, et al. Pharmacokinetics and pharmacodynamics of two oral formulations of metformin hydrochloride. Adv Ther 1994; 11: 21-33
30. Brookes LO, Sambol NC, Lin ET, et al. Effect of dosage form, dose and food on the pharmacokinetics of metformin [abstract]. Pharm Res 1991; 8 Suppl.: S320
31. Pentikäinen PJ. Bioavailability of metformin: comparison of solution, rapidly dissolving tablet, and three sustained release products. Int J Clin Pharmacol Ther Toxicol 1986; 24: 213-20
32. Beckmann R. Resorption, Verteilung im Organismus und Ausscheidung von Metformin. Diabetologia 1969; 5: 318-24
33. Vidon N, Chaussade S, Noel M, et al. Metformin in the digestive tract. Diabetes Res Clin Pract 1988; 4: 223-9
34. Bailey CJ, Wilcock C, Turner SL. Subcellular localization of metformin [abstract]. Diabetologia 1991; 34 Suppl. 2: A29
35. Debry G, Cherrier FP. Etude du mode d'excrétion du NN diméthyl-biguanide chez le diabétique adulte. Therapie 1965; 20: 351-8
36. Hermann LS. Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab 1979; 5: 233-45
37. Coetzee EJ, Jackson WP. Metformin in management of pregnant insulin-dependent diabetics. Diabetologia 1979; 16: 241-5
38. Bruneder H, Klein HJ, Isnard F, et al. Fasting metformin levels in ambulatory treated diabetic patients [abstract]. Excerpta Medica 1979; ICS 481: 33, 82P
39. Marchetti P, Gregorio F, Benzi L, et al. Diurnal pattern of plasma metformin concentrations and its relation to metabolic effects in type 2 (non-insulin-dependent) diabetic patients. Diabete Metab 1990; 16: 475-8
40. Swift CG, McLaren S, MacLean D, et al. Plasma concentrations of oral hypoglycaemic drugs in diabetic clinic patients [abstract]. Br J Clin Pharmacol 1979; 8: 406P-7P
41. Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents: an update. Clin Pharmacokinet 1989; 16: 100-28
42. Marchetti P, Benzi L, Cecchetti P, et al. Plasma biguanide levels are correlated with metabolic effects in diabetic patients. Clin Pharmacol Ther 1987; 41: 450-4
43. Marchetti P, Benzi L, Cerri M, et al. Effect of plasma metformin concentrations on serum lipid levels in type II diabetic patients. Acta Diabetol Lat 1988; 25: 55-62
44. Benzi L, Trischitta V, Ciccarone A, et al. Improvement with metformin in insulin internalization and processing in monocytes from NIDDM patients. Diabetes 1990; 39: 844-9
45. McIntyre HD, Paterson CA, Ma A, et al. Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes inellitus. Aust NZ J Med 1991; 21: 714-9
46. Hermann LS, Scherstén B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabetic Med 1994; 11: 953-60
47. Campbell IW. Metformin and the sulphonylureas: the comparative risk. Horm Metab Res 1985; 15 Suppl.: 105-11
48. Irsigler K, Kritz H, Regal H, et al. Biguanid-induzierte und Biguanid-assoziierte Laktazidose: Serum und Gewebsspiegel der Biguanide bei Hyperlaktämie und Laktazidose. Wien Klin Wochenschr 1979; 91: 59-65
49. Perrot D, Claris O, Guillaume C, et al. Metformine et acidose lactique: intérêt du dosage plasmatique initial de metformine et de l'hémodialyse. Ann Med Interne (Paris) 1986; 137: 169-70
50. Lambert H, Isnard F, Delorme N, et al. Approche physiopathologique des hyperlactatémies pathologiques chez le diabétique: intérêt de la metfonninémie. Ann Fr Anesth Reanim 1987; 6: 88-94
51. Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metformin-associated tactic acidosis. Diabetes Care 1995; 18: 779-84
52. Lacroix C, Hermelin A, Gerson M, et al. Acidose lactique imputable à la meformine. Intérêt des taux intraérythrocytaires. Presse Med 1988; 17: 1158
53. Lalau JD, Lacroix C. Lessons from in vivo and in vitro studies of metformin concentrations in plasma and in erythrocytes [abstract]. Diabetologia 1992; 35 Suppl.: A199
54. Stocks AE, Schneider JJ, Ma A, et al. Metformin therapy in chronic renal insufficiency [abstract]. Diabetic Med 1987; 4: 580A
55. Assan R, Heuclin C, Ganeval D, et al. Metformin induced lactic acidosis in the presence of acute renal failure. Diabetologia 1977; 13: 211-17
56. Lalau JD, Westeel PF, Debussche X, et al. Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin. Intensive Care Med 1987; 13: 383-7
57. Lalau JD, Debussche X, Fournier A., et al. Prise en charge et traitement de l'acidose lactique. In: Journées de Diabétologie de l'Hôtel-Dieu. Paris: Flammarion, Médecine-Sciences, 1990: 89-103
58. Lalau JD, Andrejak M, Morinière P, et al. Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol 1989; 27: 285-8
59. Morley JE, Perry HM. The management of diabetes mellitus in older individuals. Drugs 1991; 41: 548-65
60. Knight PV, Semple CG, Kesson CM. The use of metformin in the older patient. J Clin Exp Gerontol 1986; 8: 51-8
61. Chalmers J, McBain AM, Brown IRF, et al. Metformin: is its use contraindicated in the elderly? Pract Diabetes 1992; 9: 51-3
62. Alberti KGMM, Gries FA. Management of non-insulin-dependent diabetes mellitus in Europe. A consensus view. Diabetic Med 1988; 5: 275-81
63. Lalau JD, Vermersch A, Hary L, et al. Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly). Int J Clin Pharmacol Ther Toxicol 1990; 28: 329-32
64. Bismuth C, Gaultier M, Conso F, et al. Acidose lactique induite par l'ingestion excessive de metformine. Nouv Presse Med 1976; 5: 261-3
65. Larcan A, Lambert H, Ginsbourger F. Acute intoxication by metformin (instead of phenformin) hyperlactatemia reversible with extra-renal purification. Vet Hum Toxicol 1979; 21 Suppl.: 19-22
66. McLelland J. Recovery from metformin overdose. Diabetic Med 1985; 2: 410-1
67. Beaudot C, Merceron RE, Joffroy Lavieuville MJ, et al. Hyperlactacidémie réversible chez un diabétique prenant une posologie excessive de metformine. Diabete Metab 1980; 6: 199-203
68. Scheen AJ, Lefèbvre PJ. Antihyperglycaemic agents: drug interactions of clinical importance. Drug Safety 1995; 12: 32-45
69. Scheen AJ, Ferreira Alves de Magalhaes AC, Salvatore T, et al. Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest 1994; 24 Suppl. 3: 50-4
70. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-35
71. Somogyi A, Stockley C, Keal J, et al. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987; 23: 545-51
72. Gin H, Orgerie MB, Aubertin J. The influence of guar gum on absorption of metformin from the gut in healthy volunteers. Horm Metab Res 1989; 21: 81-3
73. Scheen AJ, Lefèbvre PJ. Pharmacological treatment of the obese diabetic patient. Diabete Metab 1993; 19: 547-59
74. Scheen AJ, Lefèbvre PJ. La metformine: des effets métaboliques aux indications thérapeutiques. Med Hyg (Geneve) 1993; 51: 1993-8